In leukemia and lymphoma, vitamin D exerts anti-tumor effects mediated by its binding to the vitamin D receptor (VDR). Vitamin D is related to cancer prognosis and response to therapy. However, the prevalence of vitamin D deficiency remains significantly high among the Indonesian population. This study aims to determine the profile of vitamin D and vitamin D receptor (VDR) levels in leukemia and lymphoma patients. This study design was a cross-sectional with a comparative analysis of vitamin D and its receptors, conducted on adult leukemia-lymphoma patients and control samples. Vitamin D examination was completed on 180 samples of 123 leukemia and lymphoma patients, and 57 controls. Vitamin D receptor (VDR) examination was conducted on 45 leukemia and lymphoma patients and 57 controls. The prevalence of vitamin D deficiency in the leukemia and lymphoma group was 85.4%. Subgroup analysis revealed that the prevalence of vitamin D deficiency was significantly higher in leukemia and lymphoma patients aged ≤40 years compared to their respective control group (p=0.039). There was no significant vitamin D receptor level between leukemia and lymphoma and the control group based on all age groups, male, and vitamin D status. Vitamin D receptor level was 0.53 (0.19) ng/mL in leukemia and lymphoma females, lower than the control group 0.73 (0.73) ng/mL, significantly. This study concluded that leukemia and lymphoma patients predominantly have vitamin D deficiency. Vitamin D receptor level is lower in females with leukemia and lymphoma than in the normal population. Vitamin D receptor can be considered as an adjunct marker in assessing vitamin D status in leukemia lymphoma cases. © 2026 Indonesian Journal of Clinical Pathology and Medical Laboratory. All rights reserved.